No Data
Teva Pharmaceuticals Presents 4th Interim Analysis Of PEARL Migraine Prevention Study At EAN Congress; New Sub-Analysis Highlights Potential Negative Impact Of Treatment Pauses On Patient Outcomes
4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in HelsinkiNew sub-analysis of PEARL data highlights potential neg
New AJOVY (Fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in Helsinki New sub-analysis of PEARL data highlights potential
Teva Pharmaceuticals Is Maintained at Buy by Jefferies
Teva Pharmaceuticals Is Maintained at Buy by Jefferies
Jefferies Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $23
Jefferies analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $19 to $23.
Teva Pharmaceutical Indus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 39.56% Jefferies $19 → $23 Maintains Buy 06/05/2024 27.43% Barclays $20 → $21 Maintains Overwei
Jefferies Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $23
Jefferies analyst Glen Santangelo maintains $Teva Pharmaceutical Industries(TEVA.US)$ with a buy rating, and adjusts the target price from $17 to $23.According to TipRanks data, the analyst has a succ